25 results
424B3
DMAC
DiaMedica Therapeutics Inc.
15 Oct 21
Prospectus supplement
6:32am
a significant amount of byproduct waste. Our novel recombinant manufacturing process utilizes widely available raw materials and can be readily scaled … , and their resulting ability to produce a consistent drug product. Our novel recombinant manufacturing process utilizes widely available raw
424B5
l570jw r885svlrtr
10 Aug 20
Prospectus supplement for primary offering
12:00am
8-K
EX-99.2
2pjgcjqiq
5 Aug 20
Updated Financial Information
4:33pm
424B5
b35q47eg6n78
5 Aug 20
Prospectus supplement for primary offering
4:30pm
424B5
5xyx7oy5wf
11 Feb 20
Prospectus supplement for primary offering
5:31pm
8-K
EX-99.2
234 12gmhs5eufygtp
11 Feb 20
Updated Financial Information
7:05am
424B5
9yomtfp
11 Feb 20
Prospectus supplement for primary offering
7:02am
10-K
4p0vfym7md1wfceq
19 Mar 19
Annual report
4:58pm
424B4
wrvmd1q
10 Dec 18
Prospectus supplement with pricing info
4:50pm
S-1/A
2qi7sl
19 Nov 18
IPO registration (amended)
5:01pm
S-1
EX-10.15
81zrj4k
9 Nov 18
IPO registration
4:21pm
S-1
s3axr
9 Nov 18
IPO registration
4:21pm
DRS
EX-10.15
6emffj7lb0zpy
1 Nov 18
Draft registration statement
12:00am